Asunto(s)
ADN Helicasas , Tumor del Seno Endodérmico , Proteínas Nucleares , Neoplasias de los Senos Paranasales , Factores de Transcripción , Humanos , Masculino , Tumor del Seno Endodérmico/patología , Tumor del Seno Endodérmico/metabolismo , Tumor del Seno Endodérmico/cirugía , Factores de Transcripción/metabolismo , Factores de Transcripción/genética , ADN Helicasas/metabolismo , ADN Helicasas/genética , Adulto , Anciano , Neoplasias de los Senos Paranasales/patología , Neoplasias de los Senos Paranasales/metabolismo , Neoplasias de los Senos Paranasales/cirugía , Proteínas Nucleares/metabolismo , Diagnóstico Diferencial , alfa-Fetoproteínas/metabolismo , Diferenciación Celular , Recurrencia Local de Neoplasia , GlipicanosAsunto(s)
Tumor del Seno Endodérmico , Neoplasias del Mediastino , Derrame Pleural Maligno , alfa-Fetoproteínas , Humanos , Tumor del Seno Endodérmico/diagnóstico , Tumor del Seno Endodérmico/patología , Tumor del Seno Endodérmico/metabolismo , Masculino , Neoplasias del Mediastino/patología , Neoplasias del Mediastino/diagnóstico , Neoplasias del Mediastino/metabolismo , Adulto , Estudios Retrospectivos , Derrame Pleural Maligno/patología , Derrame Pleural Maligno/diagnóstico , Adulto Joven , alfa-Fetoproteínas/metabolismo , Queratinas/metabolismo , Diagnóstico Diferencial , Factores de Transcripción/metabolismo , Glipicanos/metabolismo , Fosfatasa Alcalina/metabolismo , Proteínas Proto-Oncogénicas c-kit/metabolismo , Errores Diagnósticos , Inmunofenotipificación , Isoenzimas , Proteínas Ligadas a GPIRESUMEN
Postchemotherapy postpubertal-type yolk sac tumors (YST) with glandular and solid phenotypes are aggressive and commonly resistant to systemic chemotherapy. These neoplasms show morphologic features that significantly overlap with those of somatic carcinomas with "enteroblastic" or "fetal" phenotype (the preferred terminology depends on the site of origin). They often present as late or very late recurrences, and their diagnosis is challenging because they frequently affect patients in an age group at risk for carcinomas of somatic origin. Recently, we incidentally identified examples of postchemotherapy glandular and solid YST with "enteroblastic" phenotypes and nuclear expression of beta-catenin, prompting us to further evaluate the prevalence of this phenomenon. We found nuclear expression of beta-catenin in 10 (29%) of 34 such tumors. A subset of cases with nuclear beta-catenin expression was further analyzed with a DNA sequencing panel (n = 6) and fluorescence in situ hybridization for isochromosome 12p [i(12p); n = 5]. Sequencing identified exon 3 CTNNB1 variants in 3 (50%) of 6 analyzed cases, and fluorescence in situ hybridization was positive for i(12p) in 5 of 5 cases. In conclusion, a significant subset of postchemotherapy YST with glandular or solid architecture and "enteroblastic" phenotype demonstrates beta-catenin alterations, suggesting that activation of Wnt signaling may play a role in the progression of these neoplasms. Moreover, nuclear beta-catenin expression in these tumors represents a potential diagnostic pitfall given that carcinomas of true somatic origin with overlapping morphology may also be positive for this marker.
Asunto(s)
Tumor del Seno Endodérmico , beta Catenina , Humanos , beta Catenina/genética , beta Catenina/metabolismo , Tumor del Seno Endodérmico/patología , Tumor del Seno Endodérmico/tratamiento farmacológico , Tumor del Seno Endodérmico/genética , Tumor del Seno Endodérmico/metabolismo , Femenino , Masculino , Hibridación Fluorescente in Situ , Niño , Preescolar , Adolescente , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/análisis , Adulto , Adulto Joven , Lactante , FenotipoRESUMEN
Embryonic-type neuroectodermal elements are often intimately mixed with primitive endodermal-type glands, like those of yolk sac tumors, in germ cell neoplasia in situ (GCNIS)-derived germ cell tumors of the testis. Because the primitive glands mimic tubules or rosettes of embryonic-type neuroectodermal elements, these embryonic-type neuroectodermal/glandular complexes may be misinterpreted as pure lesions of embryonic-type neuroectodermal elements, which, if of sufficient size, may lead to a diagnosis of embryonic-type neuroectodermal tumor, despite that the criteria of the World Health Organization for a "somatic-type malignancy" are not met. A diagnosis of embryonic-type neuroectodermal tumor in the testis may lead to retroperitoneal lymphadenectomy even in clinical stage I patients, and in postchemotherapy resections indicates a poor prognosis. The distinction of the neuroectodermal and glandular elements is not always straightforward based on morphology alone. We, therefore, studied 34 testis-derived germ cell tumors with embryonic-type neuroectodermal/glandular complexes and 2 purely glandular yolk sac tumors to characterize the immunophenotypes and determine an efficient immunohistochemical panel to aid in this differential. We found that GFAP, synaptophysin, and paired-like homeobox 2B (PHOX2B) expression was specific to embryonic-type neuroectodermal elements, although PHOX2B had poor sensitivity. In contrast, positive reactions with antibodies directed against AFP, villin, and CDX2 were specific for the glandular elements, although CDX2 had poor sensitivity. Other markers, including AE1/AE3 cytokeratin, SALL4, glypican 3, SOX2, SOX11, CD56, INSM1, and neurofilament, proved less helpful because of their nonspecificity and/or poor sensitivity. We conclude that the optimal immunohistochemical panel for distinguishing the components of embryonic-type neuroectodermal/glandular complexes includes stains for synaptophysin, GFAP, villin, and AFP.
Asunto(s)
Biomarcadores de Tumor , Inmunohistoquímica , Neoplasias de Células Germinales y Embrionarias , Neoplasias Testiculares , Humanos , Masculino , Neoplasias Testiculares/patología , Neoplasias Testiculares/química , Neoplasias Testiculares/metabolismo , Neoplasias Testiculares/cirugía , Neoplasias de Células Germinales y Embrionarias/patología , Neoplasias de Células Germinales y Embrionarias/química , Neoplasias de Células Germinales y Embrionarias/metabolismo , Biomarcadores de Tumor/análisis , Adulto , Diagnóstico Diferencial , Adolescente , Persona de Mediana Edad , Tumor del Seno Endodérmico/patología , Tumor del Seno Endodérmico/química , Tumor del Seno Endodérmico/diagnóstico , Tumor del Seno Endodérmico/metabolismo , Adulto Joven , alfa-Fetoproteínas/análisis , NiñoRESUMEN
Endometrial somatically derived yolk sac tumors are characterized by yolk sac morphology with AFP, SALL-4, and/or Glypican-3 immunoexpression. Yolk sac marker expression, however, is not limited to tumors with overt yolk sac histology. Three hundred consecutive endometrial malignancies were assessed for immunomarkers of yolk sac differentiation. Of these, 9% expressed ≥1 yolk sac marker, including 29% of high-grade tumors. Only 3 (1%) met morphologic criteria for yolk sac differentiation; these were originally diagnosed as serous, high-grade NOS, and dedifferentiated carcinoma. Two were MMR-intact and comprised exclusively of yolk sac elements, while the dedifferentiated case was MMR deficient and had a background low-grade endometrioid carcinoma; this case also showed BRG1 loss. All 3 were INI1 intact. Nonspecific yolk sac marker expression was seen in 14 carcinosarcomas, 4 endometrioid, 2 serous, 1 clear cell, 1 dedifferentiated, 1 mixed serous/clear cell, and 1 mesonephric-like carcinoma. INI1 was intact in all cases; one showed BRG1 loss. Twenty were MMR-intact, and 4 were MMR deficient. All MMR-deficient cases with yolk sac marker expression, both with and without true yolk sac morphology, had no evidence of residual disease on follow-up, whereas 82% of MMR-intact cases developed recurrent/metastatic disease. In summary, endometrial somatically derived yolk sac tumors were rare but under-recognized. While AFP immunostaining was specific for this diagnosis, Glypican-3 and SALL-4 expression was seen in a variety of other high-grade carcinomas. INI1 loss was not associated with yolk sac morphology or immunomarker expression in the endometrium, and BRG1 loss was rare. All patients with MMR-deficient carcinomas with yolk sac immunoexpression +/- morphology were disease-free on follow-up, whereas the majority of MMR-intact cancers showed aggressive disease.
Asunto(s)
Biomarcadores de Tumor , Tumor del Seno Endodérmico , Neoplasias Endometriales , Inmunohistoquímica , Factores de Transcripción , Humanos , Femenino , Neoplasias Endometriales/patología , Neoplasias Endometriales/metabolismo , Biomarcadores de Tumor/análisis , Tumor del Seno Endodérmico/patología , Tumor del Seno Endodérmico/metabolismo , Anciano , Persona de Mediana Edad , Factores de Transcripción/análisis , Anciano de 80 o más Años , Adulto , Glipicanos/análisis , Glipicanos/metabolismo , Diferenciación Celular , alfa-Fetoproteínas/análisis , Incidencia , Clasificación del Tumor , ADN Helicasas/análisis , Proteínas Nucleares/análisis , Proteínas Nucleares/metabolismo , Proteína SMARCB1/análisis , Carcinoma/patología , Carcinoma/químicaRESUMEN
In the post-chemotherapy setting, germ cell tumors of the testis (GCTT) that resemble non-specific sarcomas and co-express cytokeratins and glypican-3 (GPC3) are diagnosed as "sarcomatoid yolk sac tumor postpubertal-type (YSTpt)". The diagnosis of sarcomatoid YSTpt is clinically relevant but challenging due to its rarity, non-specific histology, and negative α-fetoprotein (AFP) staining. Recently, FOXA2 has emerged as a key-gene in the reprogramming of GCTT (activating the transcription of several genes, among which GATA3), and immunohistochemical studies showed that GATA3 and FOXA2 have a higher sensitivity for non-sarcomatoid YSTpt than GPC3 and AFP. We found that sarcomatoid YSTpt did not express FOXA2 [0: 14/14 (100%)] and showed focal expression of GATA3 [0: 12/14 (85.7%), 1 + : 2/14 (14.3%)], thus suggesting that these markers are not useful in diagnosing this tumor. Furthermore, we proposed a potential mechanism of sarcomatoid transformation in the post-chemotherapy setting of GCTT, mediated by the downregulation of FOXA2 and GATA3.
Asunto(s)
Biomarcadores de Tumor , Regulación hacia Abajo , Tumor del Seno Endodérmico , Factor de Transcripción GATA3 , Factor Nuclear 3-beta del Hepatocito , Fenotipo , Neoplasias Testiculares , Factor de Transcripción GATA3/metabolismo , Factor de Transcripción GATA3/genética , Humanos , Factor Nuclear 3-beta del Hepatocito/genética , Factor Nuclear 3-beta del Hepatocito/metabolismo , Masculino , Neoplasias Testiculares/patología , Neoplasias Testiculares/genética , Neoplasias Testiculares/metabolismo , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Tumor del Seno Endodérmico/patología , Tumor del Seno Endodérmico/genética , Tumor del Seno Endodérmico/metabolismo , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/patología , Inmunohistoquímica , Glipicanos/genética , Glipicanos/metabolismo , Adulto , Sarcoma/genética , Sarcoma/patología , Sarcoma/metabolismo , Regulación Neoplásica de la Expresión Génica , Neoplasias de Células Germinales y Embrionarias/patología , Neoplasias de Células Germinales y Embrionarias/genética , Neoplasias de Células Germinales y Embrionarias/metabolismo , Adulto Joven , AdolescenteRESUMEN
BACKGROUND: Glypican-3 (GPC3) is highly expressed in testicular yolk sac tumor (TYST). GPC3 has been evaluated as a cancer vaccine for some types of tumors, but little is known on the effects of GPC3 peptide-based therapy on TYST. Here, we evaluated the antitumor effect of GPC3144-152 on TYST and its potential mechanisms. METHODS: GPC3144-152 -specific CD8+ T cells were induced by vaccine immunization and examined by ELISPOT. The CD8+ T cells were purified for testing their cytotoxicity in vitro against TYST cells by CCK-8 and TUNEL assays and in vivo against tumor growth. The influence of GPC3144-152 loading and/or cGAS silencing on the tumor growth, apoptosis and cGAS/STING signaling was tested by immunohistochemistry, immunofluorescence, flow cytometry, and Western blot. RESULTS: Vaccination with GPC3144-152 induced tumor-specific CD8+ T cells that secreted high levels of IFN-γ and granzyme B, and had potent cytotoxicity against TYST in a dose-dependent manner. Adoptive transfer of CD8+ T cells and treatment with GPC3144-152 significantly inhibited the growth of TYST tumors, but less effective for cGAS-silenced TYST tumors in vivo. Treatment with GPC3144-152 enhanced the infiltration of CD8+ T cells into the tumor environment and their cytotoxicity against TYST tumors in vivo by up-regulating granzyme B and IFN-ß expression, but down-regulating GPC3 expression in the tumors. Co-culture of CD8+ T cells with TYST in the presence of exogenous GPC3144-152 enhanced peptide-specific CD8+ T-cell cytotoxicity in vitro, accompanied by enhancing cGAS, γH2AX, TBK1, and IRF3 phosphorylation in TYST cells, but less effective in cGAS-silenced TYST cells. CONCLUSIONS: These data indicated that GPC3 peptide-specific CD8+ T cells had potent antitumor activity against TYST tumor, particularly for combined treatment with the peptide, which was partially dependent on the intratumoral cGAS/STNG signaling. GPC3 peptide vaccine may be valuable for the combination treatment of TYST.
Asunto(s)
Tumor del Seno Endodérmico , Neoplasias Testiculares , Masculino , Humanos , Linfocitos T CD8-positivos , Granzimas/metabolismo , Tumor del Seno Endodérmico/metabolismo , Glipicanos/metabolismo , Péptidos/metabolismo , Neoplasias Testiculares/metabolismo , NucleotidiltransferasasRESUMEN
BACKGROUND: Immune checkpoint blockade (ICB) is considered as a promising approach for cancer treatment. However, the potency of ICB therapy in yolk sac tumors (YSTs) has not been confirmed, and the comprehensive analysis of tumor immune microenvironment and the expression of PD-1/PD-L1 and CTLA4 were also not thoroughly evaluated. METHODS: Immunohistochemistry was performed in formalin-fixed, paraffin-embedded tumor specimens from 23 YSTs patients to detect the density and distribution of tumor-infiltrating T cells, tertiary lymphoid structures (TLSs), as well as the expression of PD-1/PD-L1 and CTLA4. RESULTS: Overall, more than half (61 %) of all patients exhibited an immune-desert phenotype based on CD3+ T cells. PD-1 expression was identified in five tumor samples (21.7 %), and PD-L1 expression exhibited a different positive rate in tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) (39.1 % and 17.4 %). Noteworthily, the rate of positive CTLA4 expression in both TCs and TILs was markedly higher (69.6 % and 56.5 %) than those of PD-1 and PD-L1 expression. Furthermore, TLSs were observed in 21.74 % of all tissues, and samples with TLSs exhibited significantly higher densities of TILs and higher expression of immune checkpoint molecules, particularly PD-1/PD-L1. In addition, tumors located in testes also exhibited a higher density of TILs and higher expression of immune checkpoint molecules. CONCLUSION: Generally a high frequency of CTLA4 expression was found, PD-1/PD-L1 expression, the immune-inflamed phenotype, and TLSs were low frequency in YSTs, however, YSTs in testes showed a higher density of TILs and higher expression of immune checkpoint molecules.
Asunto(s)
Tumor del Seno Endodérmico , Receptor de Muerte Celular Programada 1 , Humanos , Antígeno B7-H1/metabolismo , Antígeno CTLA-4/metabolismo , Tumor del Seno Endodérmico/metabolismo , Tumor del Seno Endodérmico/patología , Proteínas de Punto de Control Inmunitario/metabolismo , Linfocitos Infiltrantes de Tumor , Pronóstico , Receptor de Muerte Celular Programada 1/metabolismo , Microambiente TumoralRESUMEN
BACKGROUND: Yolk sac tumor (YST) is a germ cell tumor. It is primarily located in the gonads but can also occur extragonadally (extragonadal yolk sac tumor - EGYST), most commonly in the pelvis, retroperitoneum or mediastinum. Only a few YSTs of the urachus have been described. CASE REPORT: We present a rare case report of a 37-year-old male with episodes of macroscopic hematuria. The histological specimen obtained by transurethral resection showed a solid, and in some parts papillary infiltrative, high-grade tumor with numerous areas of marked nuclear atypia and clear invasion between the detrusor bundles. Glandular pattern has been observed in only minority of the tumor. Immunohistochemistry showed significant positivity for GPC3, SALL4 and cytokeratins AE1/AE3, while KRT7 and GATA3 were negative. We concluded that the biopsy findings were consistent with urothelial carcinoma with infrequent YST differentiation. In definitive surgical specimens we found a malignant epithelial, glandular and cystically arranged tumor of germinal appearance arising from urachus. The surrounding urothelium was free of invasive or in situ tumor changes. We reclassified the tumor as a urachal YST. CONCLUSION: EGYST was suspected because glandular and hepatoid structures were found, but the presence of these structures should be verified by immunohistochemistry.
Asunto(s)
Tumor del Seno Endodérmico/diagnóstico , Neoplasias de la Vejiga Urinaria/diagnóstico , Adulto , Biomarcadores de Tumor/metabolismo , Tumor del Seno Endodérmico/metabolismo , Tumor del Seno Endodérmico/patología , Humanos , Masculino , Neoplasias de la Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/patologíaRESUMEN
BACKGROUND: Testicular cancer constitutes 1.0% of male cancer and typically carries a good prognosis. As far as we are aware, the role for hydrogen sulfide in testicular cancer and the level of hydrogen sulfide-synthesizing enzyme have never been addressed. Here we examined cystathionine gamma-lyase (CSE) expression in several germ-cell testicular tumors. MATERIALS AND METHODS: Tissue microarrays were employed to examine CSE expression in 32 benign testicular samples, 88 testicular seminomas, 34 embryonal carcinomas, 4 mature teratomas, and 16 yolk sac tumors, and CSE expression was compared to that seen in benign testicular tissue. RESULTS: Compared to benign testicular tissue, CSE expression was increased in all three types of testicular neoplasm but not in mature teratomas. Highest CSE expression was identified in embryonal carcinomas, which often show a relatively aggressive clinical course. CONCLUSION: For the first time, we show that CSE is increased in several common testicular germ-cell tumor types.
Asunto(s)
Carcinoma Embrionario/metabolismo , Cistationina gamma-Liasa/metabolismo , Tumor del Seno Endodérmico/metabolismo , Neoplasias Testiculares/metabolismo , Regulación hacia Arriba , Estudios de Casos y Controles , Perfilación de la Expresión Génica/métodos , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Seminoma , Análisis de Matrices TisularesRESUMEN
Testicular tumors are incredibly diverse and one of the most challenging areas in surgical pathology. Because of the rarity and overlapping features with numerous entities occurring in the testis and paratestis, these tumors pose a diagnostic challenge even to the most experienced general pathologists. In 2016, the latest "World Health Organization (WHO) classification of testicular tumors" was released, which incorporated several updates to the previous 2004 classification system. These updates involved several entities, including germ cell tumors, sex cord-stromal tumors, tumors containing both germ cells and sex-cord stromal cells, a miscellaneous group of testicular tumors and paratesticular tumors. In addition, significant changes were also introduced in the 2018 AJCC TNM staging (8th edition) regarding testicular tumors. The germ cell tumors are divided into 2 major groups; tumors derived from germ cell neoplasia in situ (GCNIS) and those unrelated to GCNIS. The GCNIS associated tumors include seminomatous and nonseminomatous germ cell tumors, which constitute a heterogeneous group of tumors. Non-GCNIS-associated tumors include prepubertal-type teratoma, prepubertal yolk sac tumor, mixed prepubertal-type teratoma and yolk sac tumor and spermatocytic seminoma. In the sex cord-stromal category, the tumors are classified based on their cells of origin. Most are Leydig cell tumors and Sertoli cell tumors; however, several mixed and diverse entities based on cell types are included in this group. Gonadoblastoma is the only tumor in the mixed germ cell and sex cord-stromal tumor category. Because of recent advances in molecular techniques, abundant new genetic information has emerged which helped classify the tumors based on the molecular alterations and provided insights into the tumor pathogenesis. This review focused on the updates related to testicular germ cell tumors and sex cord-stromal tumors and described the morphologic, immunohistochemical and molecular characteristics with an aim to provide a practical diagnostic approach and an update on relevant recent molecular advances.
Asunto(s)
Tumor del Seno Endodérmico/patología , Neoplasias de Células Germinales y Embrionarias/patología , Seminoma/patología , Teratoma/patología , Neoplasias Testiculares/patología , Tumor del Seno Endodérmico/genética , Tumor del Seno Endodérmico/metabolismo , Humanos , Masculino , Estadificación de Neoplasias , Neoplasias de Células Germinales y Embrionarias/genética , Neoplasias de Células Germinales y Embrionarias/metabolismo , Seminoma/genética , Seminoma/metabolismo , Teratoma/genética , Teratoma/metabolismo , Neoplasias Testiculares/genética , Neoplasias Testiculares/metabolismoRESUMEN
Yolk-sac tumours (YSTs), a germ cell tumour subtype, occur in newborns and infants as well as in young adults of age 14-44 years. In clinics, adult patients with YSTs face a poor prognosis, as these tumours are often therapy-resistant and count for many germ cell tumour related deaths. So far, the molecular and (epi)genetic mechanisms that control development of YST are far from being understood. We deciphered the molecular and (epi)genetic mechanisms regulating YST formation by meta-analysing high-throughput data of gene and microRNA expression, DNA methylation and mutational burden. We validated our findings by qRT-PCR and immunohistochemical analyses of paediatric and adult YSTs. On a molecular level, paediatric and adult YSTs were nearly indistinguishable, but were considerably different from embryonal carcinomas, the stem cell precursor of YSTs. We identified FOXA2 as a putative key driver of YST formation, subsequently inducing AFP, GPC3, APOA1/APOB, ALB and GATA3/4/6 expression. In YSTs, WNT-, BMP- and MAPK signalling-related genes were up-regulated, while pluripotency- and (primordial) germ cell-associated genes were down-regulated. Expression of FOXA2 and related key factors seems to be regulated by DNA methylation, histone methylation / acetylation and microRNAs. Additionally, our results highlight FOXA2 as a promising new biomarker for paediatric and adult YSTs.
Asunto(s)
Biomarcadores de Tumor , Tumor del Seno Endodérmico/genética , Tumor del Seno Endodérmico/metabolismo , Factor Nuclear 3-beta del Hepatocito/genética , Factor Nuclear 3-beta del Hepatocito/metabolismo , Proteínas Oncogénicas/genética , Proteínas Oncogénicas/metabolismo , Factores de Edad , Línea Celular Tumoral , Metilación de ADN , Susceptibilidad a Enfermedades , Tumor del Seno Endodérmico/patología , Humanos , Inmunohistoquímica , Modelos BiológicosRESUMEN
Hepatocyte Nuclear Factor 1 beta (HNF1ß) is a transcription factor which plays an important role during early organogenesis, especially of the pancreato-biliary and urogenital tract. Furthermore, HNF1ß is an established marker in the differential diagnosis of ovarian cancer and shows a distinct nuclear expression in the clear cell carcinoma subtype. Recently, it has been described in yolk sac tumor, which represents a common component in many non-seminomatous germ cell tumors. Due to its broad histologic diversity, the diagnosis may be challenging and additional tools are very helpful in the workup of germ cell tumors. Immunohistochemistry was used to study HNF1ß expression in a tissue microarray (TMA) of 601 testicular germ cell tumors including seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, germ cell neoplasia in situ (GCNIS), and normal tissue. The expression pattern was compared to glypican 3 (GPC3) and α-fetoprotein (AFP), two markers currently in use for the detection of yolk sac tumor. HNF1ß showed a distinct nuclear staining in comparison to the cytoplasmic pattern of GPC3 and AFP. The sensitivity and specificity of HNF1ß were 85.4% and 96.5%, of GPC3 83.3% and 90.7%, of AFP 62.5% and 97.7%. We conclude that HNF1ß allows a reliable distinction of yolk sac tumor from other germ cell tumor components. Therefore, we propose HNF1ß as a novel and robust marker in the immunohistochemical workup of testicular germ cell tumors.
Asunto(s)
Biomarcadores de Tumor/metabolismo , Tumor del Seno Endodérmico/diagnóstico , Factor Nuclear 1-beta del Hepatocito/metabolismo , Neoplasias Testiculares/diagnóstico , Adulto , Carcinoma Embrionario/diagnóstico , Carcinoma Embrionario/metabolismo , Carcinoma Embrionario/patología , Coriocarcinoma/diagnóstico , Coriocarcinoma/metabolismo , Coriocarcinoma/patología , Diagnóstico Diferencial , Tumor del Seno Endodérmico/metabolismo , Tumor del Seno Endodérmico/patología , Humanos , Inmunohistoquímica , Masculino , Seminoma/diagnóstico , Seminoma/metabolismo , Seminoma/patología , Sensibilidad y Especificidad , Teratoma/diagnóstico , Teratoma/metabolismo , Teratoma/patología , Neoplasias Testiculares/metabolismo , Neoplasias Testiculares/patología , Testículo/metabolismo , Testículo/patología , Análisis de Matrices TisularesRESUMEN
BACKGROUND: SALL4 is a zinc finger transcription factor that exerts its physiological role during embryo-fetal development. Analyses of SALL4 expression have shown its oncogenic role in precursor B-cell lymphoblastic lymphoma, acute and chronic myeloid leukemia, gastrointestinal, breast, and lung cancers. The aim of this study was to determine the immunohistochemical profile of SALL4 in pediatric yolk sac tumors (YSTs). METHODS AND RESULTS: Immunohistochemistry detection of SALL4 was performed in 22 cases of pediatric YSTs and 10 mature teratomas. The percentage of tumor cells stained was scored as 0, 1+ (1-30% cells), 2+ (31-60%), 3+ (61-90%), and 4+ (> 90%). To compare its sensitivity and specificity with Glypican-3 and α-fetoprotein (AFP), we also stained tumors from these cases for Glypican-3 and AFP. In contrast to AFP and glypican-3, SALL4 staining in more than 90% of the tumor cells was seen in all 22 pediatric YSTs (100% sensitivity) (P < 0.001 for both SALL4 vs. AFP and SALL4 vs. glypican-3). CONCLUSIONS: SALL4 is a sensitive marker for pediatric YSTs and it can be used to distinguish them from mature teratomas. SALL4 is likely to become a new and valuable biomarker for the diagnosis of pediatric YST.
Asunto(s)
Tumor del Seno Endodérmico/metabolismo , Neoplasias Ováricas/metabolismo , Neoplasias Testiculares/metabolismo , Factores de Transcripción/biosíntesis , Biomarcadores de Tumor/biosíntesis , Niño , Tumor del Seno Endodérmico/patología , Femenino , Humanos , Inmunohistoquímica , Masculino , Neoplasias Ováricas/patología , Neoplasias Testiculares/patologíaRESUMEN
Testicular germ cell tumors are the most frequent malignancies found in men between 15 and 44 years old. Although cellular apoptosis susceptibility (CAS) was demonstrated to be upregulated in breast cancer and colon cancer, the expression of CAS in the human testis and testicular germ cell tumors remained elusive. In the present study, CAS-positive signals were detected in the normal testicular tissues, cancer adjacent normal testicular tissues, seminoma, yolk sac tumor, and teratoma. Interestingly, the expression level of CAS in testicular germ cell tumors (TGCTs) (but not seminoma) was significantly lower than that of human testicular tissues and cancer adjacent normal testicular tissues, suggesting that decreased CAS contributed to the progression of TGCTs. Notably, the expression of CAS in seminoma was significantly higher than that of in the non-seminomas, consistent with the results from TCGA database. Furthermore, the localization of CAS is mainly restricted in the nucleus in the lesions of normal human testicular tissue and cancer adjacent normal testicular tissue. Although the expression of CAS was not significantly different between normal testicular tissue and seminoma, CAS was more enriched in cytoplasm in seminoma compared to the normal, cancer adjacent tissue and other types of TGCTs. The current results demonstrated reduced expression of CAS in the human testicular germ cell tumors and the CAS translocation from the nuclear to cytoplasm in seminoma, thereby supporting a possible role in normal testis function and in the development of seminoma.
Asunto(s)
Proteína de Susceptibilidad a Apoptosis Celular/biosíntesis , Neoplasias de Células Germinales y Embrionarias/metabolismo , Neoplasias Testiculares/metabolismo , Testículo/metabolismo , Carcinoma Embrionario/metabolismo , Citoplasma/metabolismo , Tumor del Seno Endodérmico/metabolismo , Humanos , Inmunohistoquímica , Masculino , Seminoma/metabolismo , Teratoma/metabolismo , Análisis de Matrices TisularesRESUMEN
Primary mediastinal germ cell tumors are uncommon tumors that can pose diagnostic difficulties due to their morphologic spectrum and unusual site. Immunohistochemistry plays an increasing role in the diagnosis of these tumors. Whereas the immunophenotype of testicular yolk sac tumors (YST) is rather well known, the opposite is true for primary mediastinal YST leading us to investigate the immunohistochemical features of 14 such neoplasms. Fourteen cases of primary mediastinal YST were reviewed and representative whole tissue sections were selected for immunohistochemical analysis using antibodies directed against CAM5.2, SALL4, OCT3/4, glypican-3, CD30, α-fetoprotein (AFP), CD117, placental alkaline phosphatase (PLAP), GATA-3, and CDX2. The percentage of positive tumor cells and the intensity of staining were evaluated and scored. All cases (100%) showed strong and diffuse expression of CAM5.2 and SALL4, 10 cases (71%) reacted with glypican-3 and AFP in a patchy manner, 5 cases (36%) showed focal positivity with PLAP and GATA-3, 4 cases (29%) showed staining for CDX2, 3 (21%) showed expression of CD117, and a single case was positive for CD30 (7%). None of the cases showed any staining for OCT3/4. Primary mediastinal YST appear to have a similar immunohistochemical phenotype as their testicular counterparts. Coexpression of CAM5.2, SALL4, glypican-3, and AFP provides the best support for YST differentiation; however, it has to be noted that none of these markers is specific for these tumors and immunohistochemical results will always have to be interpreted in the context of morphologic, clinical, and radiologic information.
Asunto(s)
Tumor del Seno Endodérmico/metabolismo , Inmunohistoquímica/métodos , Neoplasias del Mediastino/metabolismo , Neoplasias Testiculares/metabolismo , Adolescente , Adulto , Biomarcadores/metabolismo , Diferenciación Celular , Niño , Diagnóstico Diferencial , Tumor del Seno Endodérmico/diagnóstico , Humanos , Inmunofenotipificación , Queratinas/metabolismo , Masculino , Neoplasias del Mediastino/diagnóstico , Persona de Mediana Edad , Factor 3 de Transcripción de Unión a Octámeros/metabolismo , Neoplasias Testiculares/diagnóstico , Factores de Transcripción/metabolismo , Adulto JovenAsunto(s)
Tumor del Seno Endodérmico/patología , Tumor del Seno Endodérmico/cirugía , Estómago/patología , Anciano de 80 o más Años , Tumor del Seno Endodérmico/metabolismo , Tumor del Seno Endodérmico/ultraestructura , Femenino , Gastrectomía/métodos , Derivación Gástrica/métodos , Humanos , Laparotomía/métodos , Estómago/diagnóstico por imagen , Tomografía Computarizada por Rayos X/métodos , Resultado del Tratamiento , alfa-Fetoproteínas/análisisAsunto(s)
Resistencia a Antineoplásicos , Glipicanos/metabolismo , Neoplasias de Células Germinales y Embrionarias/metabolismo , Neoplasias Testiculares/metabolismo , Regulación hacia Arriba , Adulto , Autopsia , Coriocarcinoma no Gestacional/genética , Coriocarcinoma no Gestacional/metabolismo , Coriocarcinoma no Gestacional/secundario , Cisplatino/uso terapéutico , Tumor del Seno Endodérmico/genética , Tumor del Seno Endodérmico/metabolismo , Tumor del Seno Endodérmico/secundario , Regulación Neoplásica de la Expresión Génica , Glipicanos/genética , Humanos , Masculino , Persona de Mediana Edad , Mutación , Neoplasias de Células Germinales y Embrionarias/genética , Estudios Retrospectivos , Neoplasias Testiculares/genéticaRESUMEN
AIMS: Accurate histological diagnosis and classification of germ cell tumours (GCTs) is key to informing successful therapeutic and surveillance strategy. The modern therapeutic approach for yolk sac tumour (YST) is highly curative. Because YST takes on a large morphological spectrum, it can be confused for other GCT subtypes as well as somatic carcinomas, particularly when YST presents in an extragonadal or a metastatic setting. Currently available immunohistochemical markers are limited by suboptimal sensitivity and specificity. We reported recently that ZBTB16 is a sensitive and specific marker for testicular YST. ZBTB16 is absent in other GCTs and in most common somatic carcinomas, including those of gastrointestinal, pancreatobillary, respiratory, genitourinary and gynaecological tracts. The purpose of this study is to investigate the diagnostic utility of ZBTB16 in the settings of metastatic and extragonadal YST. METHODS AND RESULTS: We studied 32 archived metastatic and four extragonadal primary YSTs as well as 51 somatic malignancies for their immunohistochemical expression of ZBTB16. For comparison, α-fetoprotein (AFP) and glypican-3 were also studied in parallel. Our results demonstrated an overall sensitivity of 91.6% for ZBTB16 in detecting metastatic and extragonadal YSTs. The non-YST elements (teratoma and embryonal carcinoma) in 15 YST-containing metastatic mixed GCTs were non-reactive. With the exception of occasional myoepithelial cells of salivary gland carcinoma, all the 51 somatic malignancies were negative for ZBTB16. CONCLUSIONS: ZBTB16 is a sensitive and specific marker for YST and is diagnostically superior to AFP and glypican-3 in metastatic and extragonadal settings.
Asunto(s)
Biomarcadores de Tumor/metabolismo , Tumor del Seno Endodérmico/metabolismo , Proteína de la Leucemia Promielocítica con Dedos de Zinc/metabolismo , Anciano , Tumor del Seno Endodérmico/patología , Femenino , Humanos , Inmunohistoquímica , Masculino , Proteínas Asociadas a Microtúbulos/metabolismo , Metástasis de la Neoplasia , Sensibilidad y Especificidad , alfa-Fetoproteínas/metabolismoRESUMEN
Yolk sac tumor of the ovary is a rare but highly malignant and aggressive germ cell tumor. The objective of this case study of an ovarian yolk sac tumor was to identify putative pathways that are known to pose a block in differentiation, both in early embryogenesis and in tumorigenesis, that might be amenable to low toxicity therapies designed to promote differentiation to a more benign state and prevent recurrent disease in such tumors. The enhancer of Zeste homolog 2 (EZH2), a histone methyl transferase, and silent mating type information regulation 2 homolog 1 (SIRT1), a NAD+ histone deacetylase, are two such pathways.